NCT06626685 Clonal Hematopoiesis of Indeterminate Potential in Heart Failure.
| NCT ID | NCT06626685 |
| Status | Recruiting |
| Phase | — |
| Sponsor | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS |
| Condition | Heart Failure |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2025-03-10 |
| Primary Completion | 2027-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2025-03-10 with a primary completion date of 2027-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is part of the Rico Macro-Project, a multidisciplinary research program promoted by FROM in collaboration with the ASST-PG23 and ATS Bergamo, aiming to investigate the role of clonal hematopoiesis on inflammation, studying in depth the mechanisms underlying the inflammatory process to determine their correlation with some important pathologies in different clinical fields (Hematology, Cardiology, Neurology, Pneumology, Gastroenterology, and Diabetology, etc.). In this context, the prospective observational study RICO-HF is developed. The RICO HF is the first project focused on CHIP and inflammation in the area of Cardiology, specifically in HF.
Eligibility Criteria
Inclusion Criteria: * consecutive patients admitted to the Cardiology Unit of the ASST Papa Giovanni XXIII Hospital, Bergamo for acute HF and patients attending the outpatient HF clinic of the same hospital for chronic HF * age \>18 years * written informed consent Exclusion Criteria: * chronic therapy with anti-inflammatories, steroids, immunomodulators, immunosuppressants, chemotherapeuthic agents * previous heart transplant * cardiogenic shock or cardiac arrest * recent acute coronary syndrome (\<3 months) * current acute infection requiring specific treatment * overt MPNs * primary myelodysplastic syndromes * malignant cancers * non-cardiovascular co-morbidity reducing life expectancy to \< 1 year * any factor precluding 1-year follow-up
Contact & Investigator
ANTONELLO GAVAZZI, MD
STUDY DIRECTOR
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Frequently Asked Questions
Who can join the NCT06626685 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06626685 currently recruiting?
Yes, NCT06626685 is actively recruiting participants. Contact the research team at agavazzi@fondazionefrom.it for enrollment information.
Where is the NCT06626685 trial being conducted?
This trial is being conducted at Bergamo, Italy, Bergamo, Italy.
Who is sponsoring the NCT06626685 clinical trial?
NCT06626685 is sponsored by FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS. The principal investigator is ANTONELLO GAVAZZI, MD at FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.